The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment -- Workshop Summary

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

HARDBACK
price:$45.00
add to cart

Rights & Permissions

Free PDF Access

Free Resources

Related Titles

The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment -- Workshop Summary (2003)
Board on Global Health (BGH)
Institute of Medicine (IOM)

Citation Manager Export the bibliographic data for this book in your chosen format
Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web.
Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book.
Reference Finder Paste in your own text to find books that relate to your topic.

Citation Manager

. "6. Emerging Tools and Technology for Countering Resistance." The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment -- Workshop Summary. Washington, DC: The National Academies Press, 2003.

Please select a format:

Page
195


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

Thornsberry C, Karlowsky JA, Sahm DF, Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Tenover FC, Ferraro MJ. 2001. Levofloxacin-resistant Streptococcus pneumoniae: second look. Antimicrobial Agents and Chemotherapy45:2183–2184.

Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Vankataraman L, Moellering RC Jr, Ferraro MJ. 2001. Linezolid resistance in a clinical isolate of Staphy lococcus aureus. Lancet358:207–208.

Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, Rahal JJ. 2001. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. Journal of Infectious Diseases184:794–798.

Walsh CT. 2000. Molecular mechanisms that confer antibacterial drug resistance. Nature 406:775–781.

Watanabe T, Morimoto A, Shiomi T. 1975. The fine structure and the protein composition of gamma phage of Bacillus anthracis. Canadian Journal of Microbiology21:1889–1892.

Weiss K, Restieri C, Gauthier R, Laverdiere M, McGeer A, Davidson RJ, Kilburn L, Bast DJ, de Azavedo J, Low DE. 2001. A nosocomial outbreak of fluoroquinolone-resistant Strep tococcus pneumoniae. Clinical Infectious Diseases33:517–522.

Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A. 2000. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. New England Jour nal of Medicine343:1917–1924.

WHO (World Health Organization). 1996. The World Health Report 1996: Fighting Dis ease, Fostering Development.Geneva: WHO.

Wong KK and Pompliano DL. 1998. Peptidoglycan biosynthesis. Unexploited antibacterial targets within a familiar pathway. Advances in Experimental Medicine and Biology 456:197–217.

Wootton M, Bowker KE, Holt HA, MacGowan AP. 2002. BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. Journal of Antimicrobial Chemotherapy49:535–539.

Young R. 1992. Bacteriophage lysis: mechanism and regulation. Microbiological Reviews 56:430–481.